Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection

Kohlstaedt, 1992, Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor, Science, 256, 1783, 10.1126/science.1377403

Murphy, 1996, Nevirapine: A review of its development, pharmacological profile and potential for use, Expert Opin Invest Drugs, 5, 1183, 10.1517/13543784.5.9.1183

Murphy, 1997, Nonnucleoside reverse transcriptase inhibitors, AIDS Clin Care, 9, 75

Montaner, 1998, A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. The INCAS trial, JAMA, 279, 930, 10.1001/jama.279.12.930

D'Aquila, 1996, Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial, Ann Intern Med, 124, 1019, 10.7326/0003-4819-124-12-199606150-00001

Vella, 25281997, Zidovudine plus didanosine plus nevirapine versus zidovudine plus didanosine in antiretroviral-naive patients with very advanced disease (Trial ISS 047), Proceedings of the International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication

Robinson, 151998, Analysis of nevirapine (NVP) effect on clinical endpoints (CEs) of HIV progression or death in ACTG Trial 193a, Program and abstracts of the Fifth Conference on Retroviruses and Opportunistic Infections

Henry, 22261997, A randomized, double-blind, placebo-controlled study comparing combination nucleoside and triple therapy for the treatment of advanced HIV disease (CD4 ≤50/mm3), Program and abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections

Price, 151998, Neurological substudies of ACTG protocol 193A: Quantitative neurological performance measures and treatment outcomes, Program and abstracts of the Fifth Conference on Retroviruses and Opportunistic Infections

Paar, 16181995, Nevirapine (NVP) in combination with zidovudine (ZDV) vs ZDV in nucleoside experienced patients, Proceedings of the 33rd Annual Meeting of the Infectious Diseases Society of America

Luzuriaga, 1997, Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection, NEJM, 336, 1343, 10.1056/NEJM199705083361902

Burchett, 151998, Virologic activity of didanosine (DDI), zidovudine (ZDV) and nevirapine (NVP) combinations in pediatric subjects with advanced disease (ACTG 245), Program and abstracts of the Fifth Conference on Retroviruses and Opportunistic Infections

Burchett, 151998, Virologic activity of didanosine (DDI), zidovudine (ZDV) and nevirapine (NVP) combinations in pediatric subjects with advanced HIV disease (ACTG 245), Program and abstracts of the Fifth Conference on Retroviruses and Opportunistic Infections

Byrnes, 1993, Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors, Antimicrob Agents Chemother, 37, 1576, 10.1128/AAC.37.8.1576

Richman, 1994, Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy, J Virol, 68, 1660, 10.1128/JVI.68.3.1660-1666.1994

Cheeseman, 1995, Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus, J Acq Immun Defic Syn Human Retrovirol, 8, 141

1998

Dusek, 2831998, Once-daily dosing of nevirapine: A retrospective, cross-study analysis, Conference record of the 12th World AIDS Conference

Dransfield, 291997

Dransfield, 91998

21997, Data on file

Beach, 1998, Chemotherapeutic agents for human immunodeficiency virus infection: Mechanism of action, pharmacokinetics, metabolism, and adverse reactions, Clin Ther, 20, 2, 10.1016/S0149-2918(98)80031-3

1998

Gottlieb, 17201995, Comparison of safety and efficacy of two doses of stavudine (ZERIT, d4T) in a large simple trial in the US parallel track program, Program and abstracts of the 35th Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy

Petersen, 1995, Dose-related activity of stavudine in patients infected with human immunodeficiency virus, J Infect Dis, 171, S131, 10.1093/infdis/171.Supplement_2.S131

Skowron, 1995, Biologic effects and safety of stavudine: Overview of Phase I and II clinical trials, J Infect Dis, 171, S113, 10.1093/infdis/171.Supplement_2.S113

1998

van Leeuwen, 1995, Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: A Phase I/II study, J Infect Dis, 171, 1166, 10.1093/infdis/171.5.1166

1998

1998

Danner, 1995, A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease, NEJM, 333, 1528, 10.1056/NEJM199512073332303

1998

Lewis, 1997, Protease inhibitors: A therapeutic breakthrough for the treatment of patients with human immunodeficiency virus, Clin Ther, 19, 187, 10.1016/S0149-2918(97)80110-5

1998

Carr, 151998, A syndrome of peripheral lipodystrophy (LD), hyperlipidemia and insulin resistance due to HIV protease inhibitors (PIs), Program and abstracts of the Fifth Conference on Retroviruses and Opportunistic Infections

Miller, 1998, Visceral abdominal-fat accumulation associated with use of indinavir, Lancet, 351, 871, 10.1016/S0140-6736(97)11518-5

Harris, 151998, One year followup of HIV patients treated with nevirapine, indinavir, and lamivudine in combination, Program and abstracts of the Fifth Conference on Retroviruses and Opportunistic Infections

Skowron, 2831998, Stavudine (d4T), nelfinavir (NFV), and nevirapine (NVP): Suppression of HIV-1 RNA to fewer than 50 copies/ml during 5 months of therapy, Conference record of the 12th World AIDS Conference

Sahai, 22261997, Drug interaction study between saquinavir (SQV) and nevirapine (NVP), Program and abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections

Lamson, 251997